A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

NCT05374525 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

287

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: APRETUDE
DRUG: Cabotegravir OLI

Sponsor

ViiV Healthcare